Literature DB >> 27314512

Traffic jams and the complex role of α-Synuclein aggregation in Parkinson disease.

Susana A Gonçalves1, Tiago Fleming Outeiro1,2,3.   

Abstract

A common pathological event among various neurodegenerative disorders (NDs) is the misfolding and aggregation of different proteins in the brain. This is thought to potentiate aberrant protein-protein interactions that culminate in the disruption of several biological processes and, ultimately, in neuronal cell loss. Although protein aggregates are a common hallmark in several disorders, the molecular pathways leading to their generation remain unclear. The misfolding and aggregation of α-Synuclein (aSyn) is the pathological hallmark of Parkinson disease (PD), the second most common age related ND. It has been postulated that oligomeric species of aSyn, rather than more mature aggregated forms of the protein, are the causative agents of cytotoxicity. In recent years, we have been investigating the molecular mechanisms underlying the initial steps of aSyn accumulation in living cells. Using an unbiased genome-wide lentiviral RNAi screen we identified trafficking and kinase genes as modulators of aSyn oligomerization, aggregation, and toxicity. Among those, Rab8b, Rab11a, Rab13 and Slp5 were found to promote the clearance of aSyn inclusions and reduce aSyn toxicity. Moreover, we found that endocytic recycling and secretion of aSyn was enhanced upon expression of Rab11a or Rab13 in cells accumulating aSyn inclusions. Altogether, our findings suggest specific trafficking steps may prove beneficial as targets for therapeutic intervention in synucleinopathies, and should be further investigated in other models.

Entities:  

Keywords:  Parkinson disease; Rab GTPases; Slp5; aggregation; neuronal trafficking; oligomerization; α-Synuclein

Mesh:

Substances:

Year:  2016        PMID: 27314512      PMCID: PMC5464113          DOI: 10.1080/21541248.2016.1199191

Source DB:  PubMed          Journal:  Small GTPases        ISSN: 2154-1248


  51 in total

1.  CC2D1A is a regulator of ESCRT-III CHMP4B.

Authors:  Nicolas Martinelli; Bettina Hartlieb; Yoshiko Usami; Charles Sabin; Aurelien Dordor; Nolwenn Miguet; Sergiy V Avilov; Euripedes A Ribeiro; Heinrich Göttlinger; Winfried Weissenhorn
Journal:  J Mol Biol       Date:  2012-03-08       Impact factor: 5.469

2.  In vivo and in vitro characterization of novel neuronal plasticity factors identified following spinal cord injury.

Authors:  Simone Di Giovanni; Andrea De Biase; Alexander Yakovlev; Tom Finn; Jeanette Beers; Eric P Hoffman; Alan I Faden
Journal:  J Biol Chem       Date:  2004-11-01       Impact factor: 5.157

3.  In vivo demonstration that alpha-synuclein oligomers are toxic.

Authors:  Beate Winner; Roberto Jappelli; Samir K Maji; Paula A Desplats; Leah Boyer; Stefan Aigner; Claudia Hetzer; Thomas Loher; Marçal Vilar; Silvia Campioni; Christos Tzitzilonis; Alice Soragni; Sebastian Jessberger; Helena Mira; Antonella Consiglio; Emiley Pham; Eliezer Masliah; Fred H Gage; Roland Riek
Journal:  Proc Natl Acad Sci U S A       Date:  2011-02-15       Impact factor: 11.205

4.  The CC2D1A, a member of a new gene family with C2 domains, is involved in autosomal recessive non-syndromic mental retardation.

Authors:  L Basel-Vanagaite; R Attia; M Yahav; R J Ferland; L Anteki; C A Walsh; T Olender; R Straussberg; N Magal; E Taub; V Drasinover; A Alkelai; D Bercovich; G Rechavi; A J Simon; M Shohat
Journal:  J Med Genet       Date:  2005-07-20       Impact factor: 6.318

5.  Alpha-synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma.

Authors:  Omar M A El-Agnaf; Sultan A Salem; Katerina E Paleologou; Leanne J Cooper; Nigel J Fullwood; Mark J Gibson; Martin D Curran; Jennifer A Court; David M A Mann; Shu-ichi Ikeda; Mark R Cookson; John Hardy; David Allsop
Journal:  FASEB J       Date:  2003-08-15       Impact factor: 5.191

6.  The plasma alpha-synuclein levels in patients with Parkinson's disease and multiple system atrophy.

Authors:  P H Lee; G Lee; H J Park; O Y Bang; I S Joo; K Huh
Journal:  J Neural Transm (Vienna)       Date:  2006-02-09       Impact factor: 3.575

7.  Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation.

Authors:  Jia-Yi Li; Elisabet Englund; Janice L Holton; Denis Soulet; Peter Hagell; Andrew J Lees; Tammaryn Lashley; Niall P Quinn; Stig Rehncrona; Anders Björklund; Håkan Widner; Tamas Revesz; Olle Lindvall; Patrik Brundin
Journal:  Nat Med       Date:  2008-04-06       Impact factor: 53.440

8.  A striatal-enriched intronic GPCR modulates huntingtin levels and toxicity.

Authors:  Yuwei Yao; Xiaotian Cui; Ismael Al-Ramahi; Xiaoli Sun; Bo Li; Jiapeng Hou; Marian Difiglia; James Palacino; Zhi-Ying Wu; Lixiang Ma; Juan Botas; Boxun Lu
Journal:  Elife       Date:  2015-03-04       Impact factor: 8.140

9.  The small GTPase Rab11 co-localizes with α-synuclein in intracellular inclusions and modulates its aggregation, secretion and toxicity.

Authors:  Oldriska Chutna; Susana Gonçalves; Anna Villar-Piqué; Patrícia Guerreiro; Zrinka Marijanovic; Tiago Mendes; José Ramalho; Evangelia Emmanouilidou; Salvador Ventura; Jochen Klucken; Duarte C Barral; Flaviano Giorgini; Kostas Vekrellis; Tiago F Outeiro
Journal:  Hum Mol Genet       Date:  2014-08-04       Impact factor: 6.150

10.  α-Synuclein interacts with the switch region of Rab8a in a Ser129 phosphorylation-dependent manner.

Authors:  Guowei Yin; Tomas Lopes da Fonseca; Sibylle E Eisbach; Ane Martín Anduaga; Carlo Breda; Maria L Orcellet; Éva M Szegő; Patricia Guerreiro; Diana F Lázaro; Gerhard H Braus; Claudio O Fernandez; Christian Griesinger; Stefan Becker; Roger S Goody; Aymelt Itzen; Flaviano Giorgini; Tiago F Outeiro; Markus Zweckstetter
Journal:  Neurobiol Dis       Date:  2014-06-28       Impact factor: 5.996

View more
  5 in total

Review 1.  Consequences of Rab GTPase dysfunction in genetic or acquired human diseases.

Authors:  Marcellus J Banworth; Guangpu Li
Journal:  Small GTPases       Date:  2017-12-28

2.  Synuclein impairs trafficking and signaling of BDNF in a mouse model of Parkinson's disease.

Authors:  Fang Fang; Wanlin Yang; Jazmin B Florio; Edward Rockenstein; Brian Spencer; Xavier M Orain; Stephanie X Dong; Huayan Li; Xuqiao Chen; Kijung Sung; Robert A Rissman; Eliezer Masliah; Jianqing Ding; Chengbiao Wu
Journal:  Sci Rep       Date:  2017-06-20       Impact factor: 4.379

3.  Single Molecule Fingerprinting Reveals Different Amplification Properties of α-Synuclein Oligomers and Preformed Fibrils in Seeding Assay.

Authors:  Derrick Lau; Chloé Magnan; Kathryn Hill; Antony Cooper; Yann Gambin; Emma Sierecki
Journal:  ACS Chem Neurosci       Date:  2022-03-14       Impact factor: 4.418

Review 4.  Roles of dual specificity tyrosine-phosphorylation-regulated kinase 2 in nervous system development and disease.

Authors:  Gabriel Nicolás Santos-Durán; Antón Barreiro-Iglesias
Journal:  Front Neurosci       Date:  2022-09-08       Impact factor: 5.152

Review 5.  α-Synuclein Trafficking in Parkinson's Disease: Insights From Fly and Mouse Models.

Authors:  Jingjing Cheng; Qingqing Lu; Li Song; Margaret S Ho
Journal:  ASN Neuro       Date:  2018 Jan-Dec       Impact factor: 4.146

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.